Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders... Show more
Bristol-Myers Squibb operates in a competitive biopharmaceutical landscape where demand for advanced therapies remains robust. Recent trading activity has been influenced by sector rotation and general market sentiment toward healthcare equities. The stock trades within a range consistent with peers, reflecting balanced investor views on its fundamentals and growth prospects.
Bristol-Myers Squibb develops and commercializes medicines primarily in oncology, hematology, immunology, and cardiovascular disease. Its business model centers on high-value prescription pharmaceuticals, with major products including Opdivo for cancer immunotherapy and Eliquis for anticoagulation. The company holds a leading position in immuno-oncology and benefits from extensive clinical trial expertise and global manufacturing capabilities. Competitive advantages stem from its research pipeline, intellectual property portfolio, and collaborations with academic institutions and biotechnology firms.
Over the past month, Bristol-Myers Squibb advanced several clinical programs in oncology and immunology. The company reported progress on pipeline candidates and maintained focus on cost management initiatives. Broader industry factors, including evolving reimbursement policies and ongoing innovation in targeted therapies, continue to shape sentiment. No single event dominated price action, with performance aligning with typical volatility in the pharmaceutical sector.
Tickeron provides access to hundreds of AI trading bots that analyze and trade thousands of tickers across various markets. The curated Trending AI Robots section highlights only the top-performing and most relevant bots based on recent results. These automated strategies differ in approach, holding periods, and performance indicators, allowing users to explore options suited to different trading styles. Review the selection and consider how these tools may complement your own analysis. Trending AI Robots
Looking ahead, Bristol-Myers Squibb investors will focus on upcoming clinical trial readouts, potential regulatory approvals for new indications, and updates on product launches. Key themes include competition in the oncology space, pricing pressures, and opportunities in emerging therapeutic areas. Macroeconomic conditions affecting healthcare budgets and any shifts in industry consolidation trends also warrant attention. Monitoring quarterly results and management commentary will provide further insight into execution on strategic priorities.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsThe Moving Average Convergence Divergence (MACD) for BMY turned positive on June 26, 2026. Looking at past instances where BMY's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BMY's RSI Indicator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 26, 2026. You may want to consider a long position or call options on BMY as a result. In of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
BMY moved above its 50-day moving average on July 02, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMY advanced for three days, in of 300 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BMY broke above its upper Bollinger Band on June 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMY entered a downward trend on June 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.743) is normal, around the industry mean (19.576). P/E Ratio (15.810) is within average values for comparable stocks, (26.499). Projected Growth (PEG Ratio) (1.466) is also within normal values, averaging (4.388). Dividend Yield (0.044) settles around the average of (0.031) among similar stocks. P/S Ratio (2.376) is also within normal values, averaging (3.942).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BMY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceuticals products
Industry PharmaceuticalsMajor